不可切除NSCLC接受cCRT联合巩固免疫治疗中加入诱导治疗的有效性和安全性：一项回顾性研究
Efficacy and safety of adding induction therapy for unresectable NSCLC receiving cCRT and consolidation immunotherapy: A retrospective study.
作者
作者单位
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
摘要
中文
同步放化疗后巩固免疫治疗是不可切除局部晚期非小细胞肺癌的标准治疗方案。这项回顾性研究纳入168例患者，使用稳定逆概率加权平衡基线特征后，比较加入诱导治疗与单纯cCRT+ICI的生存和安全性结局。调整后，诱导化疗仅在肿瘤对诱导有反应的患者中延长无进展生存期（PFS），而诱导化免联合治疗相比标准治疗和单纯诱导化疗显著改善PFS，且未增加严重毒性事件。各组间总生存期无差异。该真实世界证据阐明了不同诱导策略的独特临床价值，并为该患者群体的个体化治疗选择提供指导。
English
Concurrent chemoradiotherapy followed by consolidation immunotherapy is standard of care (SOC) for unresectable locally advanced non-small cell lung cancer. This retrospective study enrolled 168 patients to compare survival and safety outcomes of the addition of induction therapy compared with the cCRT+ICI alone, with stabilized inverse probability weighting used to balance baseline patient characteristics. After adjustment, induction chemotherapy only prolonged progression-free survival (PFS) in patients with tumor response to induction, whereas induction chemoimmunotherapy significantly improved PFS relative to both standard treatment and induction chemotherapy, without increasing severe toxic events. No overall survival differences existed across groups. This real-world evidence clarifies the distinct clinical value of different induction strategies and guides personalized treatment selection for this patient population.
分类与指标
- 研究类型
- 临床研究
- 病种
- 肺癌
- JCR 分区
- Q1
- 影响因子
- 4.5
- 新锐分区
- 3区